158 related articles for article (PubMed ID: 36621463)
21. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
22. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
23. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
24. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
[TBL] [Abstract][Full Text] [Related]
25. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.
Sari Motlagh R; Abufaraj M; Karakiewicz PI; Rajwa P; Mori K; Mun DH; Shariat SF
World J Urol; 2022 Apr; 40(4):907-914. PubMed ID: 34477955
[TBL] [Abstract][Full Text] [Related]
26. Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis.
Qazi SU; Altaf Z; Zafar M; Tariq MA; Khalid A; Kaleem A; Saad E; Qazi S
Prostate; 2024 May; 84(6):525-538. PubMed ID: 38372065
[TBL] [Abstract][Full Text] [Related]
27. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
Eur Urol; 2013 Jul; 64(1):159-66. PubMed ID: 22537796
[TBL] [Abstract][Full Text] [Related]
28. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
[TBL] [Abstract][Full Text] [Related]
29. Effects of Androgen Deprivation Therapy on COVID-19 in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.
Karimi A; Nowroozi A; Alilou S; Amini E
Urol J; 2021 Jul; 18(6):577-584. PubMed ID: 34302737
[TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
Davidsson S; Messing Eriksson A; Udumyan R; Swanholm P; Lewin Lundh M; Widing C; Lindlöf C; Fridfeldt J; Andersson SO; Fall K
Prostate; 2023 May; 83(6):555-562. PubMed ID: 36658755
[TBL] [Abstract][Full Text] [Related]
31. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
32. Androgen deprivation therapy: indications, methods of utilization, side effects and their management.
Magee DE; Singal RK
Can J Urol; 2020 Feb; 27(27 Suppl 1):11-16. PubMed ID: 32101695
[TBL] [Abstract][Full Text] [Related]
33. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
34. Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis.
Cui H; Wang Y; Li F; He G; Jiang Z; Gang X; Wang G
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):15-23. PubMed ID: 32814845
[TBL] [Abstract][Full Text] [Related]
35. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
[TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.
Alwhaibi A; Alsanea S; Almadi B; Al-Sabhan J; Alosaimi FD
Aging Male; 2022 Dec; 25(1):101-124. PubMed ID: 35343371
[No Abstract] [Full Text] [Related]
37. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.
Tae BS; Jeon BJ; Choi H; Bae JH; Park JY
Cancer Med; 2019 Aug; 8(9):4475-4483. PubMed ID: 31183968
[TBL] [Abstract][Full Text] [Related]
38. Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer.
Gong J; Payne D; Caron J; Bay CP; McGregor BA; Hainer J; Partridge AH; Neilan TG; Di Carli M; Nohria A; Groarke JD
JACC CardioOncol; 2020 Nov; 2(4):553-563. PubMed ID: 34396266
[TBL] [Abstract][Full Text] [Related]
39. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
[TBL] [Abstract][Full Text] [Related]
40. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]